Charter Research - Winter Park

Running trials

• Not yet recruiting

  A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Phase 2· Source

• Recruiting

  A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608· Phase 2· Source

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

  NCT06859268· Phase 3· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Source

• Recruiting

  A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  NCT06143956· Phase 2· Source

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Type 2 diabetes2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

  NCT07030868· Phase 2· Source

• Withdrawn

  A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06901349· Phase 2· Source

• Completed

  A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06683508· Phase 2· Source

• Completed

  A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06603571· Phase 2· Source

• Completed

  A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06230523· Phase 2· Source

• Completed

  A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06124807· Phase 2· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Source

• Completed

  A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  NCT05395481· Phase 1· Source